Knight Therapeutics Inc. (GUD : TSX)
Common Stock
$11.30
CAD
+0.04 (0.36%)
Last updated: 2026-11-04
Follow GUD
GUD
Knight Therapeutics Inc.
WealthAwesomePerformance
1 Day
+0.36%
1 Week
-0.09%
1 Month
+9.07%
YTD
+91.20%
Key Statistics
Market Cap
$1.11B
52W High
$11.83
52W Low
$5.66
P/E Ratio
75.33
50 Day MA
$10.48
200 Day MA
$8.58
Beta
0.02
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/4/2026 | $11.31 | $11.31 | $10.90 | $11.30 | $11.30 | 66,510 |
| 11/3/2026 | $11.32 | $11.33 | $11.18 | $11.26 | $11.26 | 28,456 |
| 11/2/2026 | $11.34 | $11.44 | $11.26 | $11.32 | $11.32 | 71,442 |
| 10/30/2026 | $11.34 | $11.41 | $11.25 | $11.27 | $11.27 | 15,721 |
| 10/29/2026 | $11.34 | $11.43 | $11.28 | $11.40 | $11.40 | 62,633 |
| 10/28/2026 | $11.28 | $11.41 | $11.23 | $11.31 | $11.31 | 42,341 |
| 10/27/2026 | $11.63 | $11.66 | $11.21 | $11.28 | $11.28 | 73,187 |
| 10/26/2026 | $11.60 | $11.64 | $11.45 | $11.63 | $11.63 | 68,191 |
| 10/23/2026 | $11.70 | $11.71 | $11.51 | $11.61 | $11.61 | 29,570 |
| 10/22/2026 | $11.70 | $11.83 | $11.55 | $11.70 | $11.70 | 61,578 |
Analyst Price Targets
Based on analyst covering GUD · as of Oct 19, 2026
Wall Street analysts forecast GUD stock price to rise 3.1% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.65
+3.1% Upside
Previously C$11.19 on Sep 17, 2026
Current Price
C$11.30
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
23.1%
Annualized
90-Day Vol
26.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$13.51
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$11.99 | C$11.07 – C$12.99 |
| 60 trading days | C$12.73 | C$11.37 – C$14.25 |
| 90 trading days | C$13.51 | C$11.77 – C$15.51 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Knight Therapeutics Inc.
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Financials
- Revenue (TTM)
- $547.31M
- EBITDA
- $81.16M
- Profit Margin
- 2.72%
- ROE (TTM)
- 1.91%
- EPS (Diluted)
- 0.15
- Book Value
- 8.13
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About GUD
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| AAB | Aberdeen International Inc. | $0.02 | +33.33% |
| XMF-A | M Split Corp | $1.99 | +17.06% |
| CNT | Century Global Commodities Corp | $0.04 | +16.67% |
| LABS | Medipharm Labs Corp | $0.07 | +16.67% |
| HSTR | Heliostar Metals Ltd. | $2.24 | +15.46% |
| DSV | Discovery Silver Corp. | $11.09 | +15.28% |
| PRL | Propel Holdings Inc | $30.53 | +15.16% |
| HMM-A | Hammond Manufacturing Company Limited | $30.00 | +15.03% |
GUD.TO news timeline
15 articles covering GUD.TO, most recent first
LatestWhat's Going On With Knight Therapeutics Inc. Stock Tuesday?
September 2026
August 2026
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock is tanking today
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock fell yesterday
- Why Knight Therapeutics Inc. stock fell yesterday
- Knight Therapeutics Inc. GUD Earnings Miss Estimates by 188.0%
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock is rising today